|
Baseline characteristics
|
ACTG cohort (n = 102)
|
BLIR study cohort (n = 20)
|
Total (n = 122)
|
|---|
|
Age (years)
|
39 (18 – 64)
|
37 (30 – 51)
|
39 (18 – 64)
|
|
Sex
|
Female
|
21 (21%)
|
3 (15%)
|
24 (20%)
|
|
Male
|
81 (79%)
|
17 (85%)
|
98 (80%)
|
|
Race
|
Caucasian Non-Hispanic
|
51 (50%)
|
5 (25%)
|
56 (46%)
|
|
African American Non-Hispanic
|
19 (19%)
|
14 (70%)
|
33 (27%)
|
|
Hispanic
|
30 (29%)
|
1 (5%)
|
31 (25%)
|
|
Other
|
2 (2%)
|
0
|
2 (2%)
|
|
BMI
|
25.7 (18.6 – 47.2)
|
23.3 (18.9 – 35.5)
|
25.4 (18.6 – 47.2)
|
|
Prior Smoking History
|
Yes
|
52 (51%)
|
16 (80%)
|
68 (56%)
|
|
No
|
50 (49%)
|
4 (20%)
|
54 (44%)
|
|
CD4+ T-cells (cells/mm3)
|
288 (8 – 980)
|
72.5 (3 – 268)
|
256 (3 – 980)
|
|
Viral load (log10RNA copies/mL)
|
4.61 (2.28 – 5.99)
|
5.3 (2.15 – 6.14)
|
4.67 (2.15 – 6.14)
|
|
ART Regimen
|
NNRTI + NRTI
|
42 (41%)
|
0
|
42 (34)
|
|
PI + NRTI
|
39 (38%)
|
20 (100%)
|
59 (48%)
|
|
RAL + NRTI
|
19 (19%)
|
0
|
19 (16%)
|
|
Other
|
2 (2%)
|
0
|
2 (2)
|
|
HBV Infection
|
Positive
|
1 (1%)
|
No data
|
No data
|
|
Negative
|
101 (99%)
|
No data
|
No data
|
|
HCV Infection
|
Positive
|
3 (3%)
|
No data
|
No data
|
|
Negative
|
99 (97%)
|
No data
|
No data
|
- Continuous variables are presented as median (range). Categorical variables are presented as count (percentage)
- ACTG AIDS Clinical Trials Group, BLIR Bone Loss and Immune Reconstitution, BMI body mass index, HBV hepatitis B virus, HCV hepatitis C virus
